| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.24M | 49.67M | 63.16M | 74.14M | 96.09M | 95.23M |
| Gross Profit | 21.79M | 21.26M | 35.57M | 19.41M | 48.59M | 52.26M |
| EBITDA | -13.60M | -22.01M | -24.90M | -41.68M | -38.03M | -44.49M |
| Net Income | -21.69M | -29.85M | -23.80M | -59.31M | -137.72M | -30.68M |
Balance Sheet | ||||||
| Total Assets | 81.60M | 113.44M | 152.55M | 187.64M | 171.51M | 310.88M |
| Cash, Cash Equivalents and Short-Term Investments | 9.81M | 22.62M | 48.99M | 69.28M | 20.42M | 55.55M |
| Total Debt | 1.40M | 59.34M | 60.44M | 57.63M | 22.60M | 23.36M |
| Total Liabilities | 72.35M | 86.36M | 96.99M | 110.14M | 41.07M | 56.65M |
| Stockholders Equity | 9.25M | 27.09M | 55.56M | 77.50M | 130.45M | 254.23M |
Cash Flow | ||||||
| Free Cash Flow | -14.91M | -25.11M | -19.08M | -5.58M | -34.48M | -76.85M |
| Operating Cash Flow | -14.04M | -21.26M | -15.39M | -5.32M | -29.56M | -48.59M |
| Investing Cash Flow | -726.00K | -3.80M | -3.51M | 395.00K | -11.79M | -19.44M |
| Financing Cash Flow | -46.00K | -145.00K | -251.00K | 52.39M | 8.04M | 55.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $59.44M | ― | -21.73% | ― | 43.56% | -349.41% | |
48 Neutral | $33.25M | 183.33 | 7.78% | ― | 28.55% | ― | |
46 Neutral | $29.44M | -0.97 | -109.83% | ― | -4.23% | 37.33% | |
46 Neutral | $82.83M | ― | -9.90% | ― | 23.29% | 33.65% | |
44 Neutral | C$19.83M | ― | -7.43% | ― | 19.66% | 84.34% | |
41 Neutral | $28.86M | -18.28 | -77.67% | ― | 2.41% | 74.61% |
Charlotte’s Web Holdings, Inc., a Certified B Corp headquartered in Louisville, Colorado, operates in the wellness sector, focusing on the production and sale of high-quality hemp-derived products such as CBD oils, gummies, and topicals. The company is engaged in research and development through its CW Labs division, exploring the potential health benefits of hemp-based compounds and other botanical products.
ONE HEMP is calling for immediate action against new federal hemp restrictions that impose a 0.4 mg total THC limit on full-spectrum CBD products, arguing this limit is unscientific and threatens consumer access to safe wellness products. The coalition is mobilizing efforts to promote science-based regulations that differentiate between legitimate CBD products and harmful synthetics, with legislative solutions being prepared by both the House and Senate to ensure consumer safety and industry innovation.
The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Charlotte’s Web Holdings announced its Q3 2025 results, highlighting strategic transformations aimed at improving performance in 2026. The company has internalized its Brightside™ gummy production, enhancing manufacturing capacity and cost efficiency. A new Scientific Advisory Board has been formed to bolster its medical channel strategy and support its research and development efforts. Additionally, Charlotte’s Web has restructured its B2B retail operations to adapt to regulatory changes, focusing on top revenue-generating customers and building infrastructure for medical practitioners.
The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Charlotte’s Web Holdings has appointed M. Borgia Walker to its Board of Directors, effective November 1, 2025. Walker brings three decades of experience in transformation and financial leadership from the global consumer goods and financial services industries. Her expertise in organizational transformation, finance, and regulatory compliance is expected to support Charlotte’s Web’s strategic objectives and enhance its market leadership. This appointment aligns with the company’s values of sustainability and social responsibility, and is seen as a strategic move to strengthen its board and continue its growth trajectory.
The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Charlotte’s Web Holdings has expanded its Brightside line with the launch of Knockout Hemp THC Sleep Gummies, designed to enhance sleep quality by combining hemp-derived THC and CBN with a rapid-onset delivery system. This new product aims to capture the growing demand for natural sleep solutions, reinforcing the company’s position as a leader in the hemp wellness category and broadening its portfolio of science-backed formulations.
The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Charlotte’s Web Holdings has launched Quiet Sleep Mushroom Gummies, expanding its product line in the sleep and relaxation category. This new melatonin-free and CBD-free product, which combines reishi mushroom, chamomile, and magnesium, addresses consumer demand for natural sleep aids and positions the company to capitalize on the growing functional mushroom and sleep-support markets.
On September 16, 2025, Jonathan Atwood announced his resignation from the Board of Directors at Charlotte’s Web Holdings, effective October 1, 2025. His departure is not due to any disagreements with the company’s operations, policies, or financial practices, indicating a smooth transition without internal conflict.
Charlotte’s Web Holdings, a leader in hemp-derived CBD wellness, has announced the formation of a Scientific Advisory Board to enhance its medical strategy and accelerate research and development efforts. This initiative aims to strengthen the company’s focus on science-backed innovation and expand patient access to plant-based therapeutics. The board will guide clinical initiatives and product formulations, addressing gaps in patient care for conditions like pain and anxiety. Additionally, the company is collaborating with DeFloria, Inc. and Ajna BioSciences PBC on a botanical drug candidate for autism spectrum disorder, which has received FDA approval for Phase 2 clinical trials.
Charlotte’s Web Holdings’ latest earnings call revealed a cautiously optimistic outlook amidst ongoing challenges. The company demonstrated positive revenue growth and strategic expansion, despite facing industry headwinds and regulatory uncertainty. Cost-saving measures and innovative product launches are positioning the company for future profitability, although current financials still reflect challenges with negative EBITDA and net loss.